Overview

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Status:
Terminated
Trial end date:
2012-04-12
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer. Pazopanib hydrochloride and anastrozole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride and anastrozole together before surgery may make the tumor smaller and reduce the amount of normal cells that have to be removed
Phase:
Phase 2
Details
Lead Sponsor:
University of Arizona
Collaborators:
GlaxoSmithKline
National Cancer Institute (NCI)
Treatments:
Anastrozole